Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Kidney Cancers: early-phase trial registry
3 of 3 indexed Kidney Cancers trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Kidney Cancers: 3 US clinical trials tracked, 3 recruiting.
Kidney Cancers is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Neomorph, running 1 of these trials.
Enrollment posture brief
Registry condition kidney-cancers
OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Kidney Cancers lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Kidney Cancers on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Kidney Cancers is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
NCT07050771
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Cancer Institute (NCI)
NCT06479811
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph
NCT07300241
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Kidney Cancers records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Kidney Cancers trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Kidney Cancers page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Kidney Cancers trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Neomorph sponsors the most Kidney Cancers trials on record, review their full trial history before evaluating a specific study. See Neomorph's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Cancers condition card totals 3 registered trials; most-linked intervention NEO-811; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.